161 related articles for article (PubMed ID: 16728542)
1. Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions.
Lazaris AC; Tseleni-Balafouta S; Papathomas T; Brousalis T; Thomopoulou G; Agrogiannis G; Patsouris ES
Eur J Endocrinol; 2006 Jun; 154(6):827-33. PubMed ID: 16728542
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of Insulin-like growth factor-1, Transforming growth factor-beta1, and Vascular endothelial growth factor in parathyroid adenoma and hyperplasia.
Sayar H; Sahin M; Dogan PO; Karabulut S; Seringec N; Oguz A
Indian J Pathol Microbiol; 2014; 57(4):549-52. PubMed ID: 25308005
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions.
Thomopoulou GE; Tseleni-Balafouta S; Lazaris AC; Koutselini H; Kavantzas N; Davaris PS
Eur J Endocrinol; 2003 Jan; 148(1):81-7. PubMed ID: 12534361
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism.
Martins P; Schmitt F; Almeida H; Frazão JM
Nephrol Dial Transplant; 2008 Sep; 23(9):2889-94. PubMed ID: 18398016
[TBL] [Abstract][Full Text] [Related]
5. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
6. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
[TBL] [Abstract][Full Text] [Related]
7. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
8. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.
Yamaguchi S; Yachiku S; Morikawa M
J Clin Endocrinol Metab; 1997 Aug; 82(8):2681-8. PubMed ID: 9253354
[TBL] [Abstract][Full Text] [Related]
9. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity.
Loda M; Lipman J; Cukor B; Bur M; Kwan P; DeLellis RA
Hum Pathol; 1994 Oct; 25(10):1050-6. PubMed ID: 7927309
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in primary hyperparathyroidism.
Segiet OA; Michalski M; Brzozowa-Zasada M; Piecuch A; Żaba M; Helewski K; Gabriel A; Wojnicz R
Ann Diagn Pathol; 2015 Apr; 19(2):91-8. PubMed ID: 25648902
[TBL] [Abstract][Full Text] [Related]
11. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas.
Yano S; Sugimoto T; Tsukamoto T; Chihara K; Kobayashi A; Kitazawa S; Maeda S; Kitazawa R
Eur J Endocrinol; 2003 Apr; 148(4):403-11. PubMed ID: 12656660
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions.
Garcia de la Torre N; Buley I; Wass JA; Jackson DG; Turner HE
J Clin Endocrinol Metab; 2004 Jun; 89(6):2890-6. PubMed ID: 15181073
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
15. Expression of TRAIL and Fas in Primary Hyperparathyroidism.
Segiet OA; Deska M; Mielańczyk Ł; Brzozowa-Zasada M; Buła G; Gawrychowski J; Wojnicz R
J Invest Surg; 2017 Aug; 30(4):242-246. PubMed ID: 27763797
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas.
Kayath MJ; Martin LC; Vieira JG; Roman LM; Nosé-Alberti V
Eur J Endocrinol; 1998 Jul; 139(1):78-83. PubMed ID: 9703382
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study.
Vasef MA; Brynes RK; Sturm M; Bromley C; Robinson RA
Mod Pathol; 1999 Apr; 12(4):412-6. PubMed ID: 10229506
[TBL] [Abstract][Full Text] [Related]
18. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
19. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.
Kifor O; Moore FD; Wang P; Goldstein M; Vassilev P; Kifor I; Hebert SC; Brown EM
J Clin Endocrinol Metab; 1996 Apr; 81(4):1598-606. PubMed ID: 8636374
[TBL] [Abstract][Full Text] [Related]
20. [Nuclear DNA content of parathyroid tumor with hyperparathyroidism].
Suzuki S; Ando Y; Ami H; Furukawa H; Tsuchiya A; Abe R
Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():486-91. PubMed ID: 9589058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
